TP53 and cancer: Loss of function (LOF) mutations made up about 20% of all mutations in both cancer types, and unclassified TP53 mutations, which are point mutations not known to be oncomorphic, made up 43.7% of endometrial cancers and 59.1% of ovarian cancers.